EUVIMEDEUVIMED entdecken
Übersichtsarbeit

S1PR-Targeted PET Imaging: Advancing Insights into Neuroinflammatory and Immune-Related Pathologies

Ruolin Wu, Jian Rong, Yuyue Hou, Chenru Yin, Yan Zhou, Yongkang Gai iD, Achi Haider iD, Xiaoli Lan iD, Steven H Liang iD, Zairong Gao, Xiaotian Xia iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Ruolin Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HB 430022, China. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Sphingosine-1-Phosphate Receptors, Neuroinflammatory Diseases. Die Arbeit nennt 94 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province, National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sphingosine-1-phosphate (S1P) and its receptors (S1PRs) are pivotal regulators of immune cell trafficking, vascular integrity, and various physiological processes, playing key roles in the pathogenesis of neuroinflammatory and immune-related disorders. Among these, multiple sclerosis (MS) is the most common chronic inflammatory condition affecting the central nervous system (CNS), marked by autoimmune-induced neurodegeneration, inflammation, and ongoing demyelination. FTY720, known as fingolimod or Gilenya, is an immunomodulatory medication that was approved in 2010 as the first oral therapy for relapsing-remitting MS. Upon phosphorylation, FTY720 mimics S1P and binds selectively to all S1PR subtypes, except S1PR2, underscoring the therapeutic possibilities of focusing on the S1P-S1PR signaling axis for neuroinflammatory conditions. This success emphasizes the relevance of S1P-mediated pathways in both disease mechanisms and treatment strategies. Emerging precision medicine approaches emphasize the importance of noninvasive imaging to elucidate molecular mechanisms in vivo. Positron emission tomography (PET) imaging-utilizing suitable radioactive tracers to probe biological targets and processes in vivo-offers a transformative approach to quantifying receptor expression, thereby delineating crucial insights into disease diagnosis, therapy monitoring, and therapeutic drug development. As such, S1PR-specific PET imaging provides a promising approach to explore the pivotal role of S1PRs in MS and other immune-mediated diseases. This review offers a comprehensive overview of the development and clinical applications of S1PR-targeted PET radiopharmaceuticals, illustrating their potential to transform therapeutic strategies. Further, recent advances in radiopharmaceutical design have yielded S1PR-targeted PET probes with high specificity, improved metabolic stability, and enhanced blood-brain barrier penetration, addressing key challenges in imaging neuroinflammation. Additionally, it critically discusses future directions for S1PR-targeted PET imaging in advancing our understanding of disease mechanisms, improving patient outcomes, and contributing to the broader vision of precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographySphingosine-1-Phosphate ReceptorsNeuroinflammatory DiseasesHumansAnimalsSphingosineLysophospholipidsFingolimod HydrochlorideMultiple SclerosisRadiopharmaceuticals

Stichwörter der Autor:innen

PETmultiple sclerosisneuroinflammatoryradiopharmaceuticalssphingosine-1-phosphate receptors

Substanzen

Sphingosine-1-Phosphate ReceptorsSphingosinesphingosine 1-phosphateLysophospholipidsFingolimod HydrochlorideRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HB 430022, China.
  • Hubei Province Key Laboratory of Molecular Imaging, Wuhan, HB 430022, China.
  • Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, HB 430022, China.
  • Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.
  • Hubei Academy of Scientific and Technical Information, Wuhan, HB 430070, China.

ORCID-Profile: Yongkang Gai, Achi Haider, Xiaoli Lan, Steven H Liang, Xiaotian Xia

Förderung

  • Natural Science Foundation of Hubei Province
  • National Science and Technology Major Project

Zitieren

APA

Wu, R., Rong, J., Hou, Y., Yin, C., Zhou, Y., Gai, Y., Haider, A., Lan, X., Liang, S. H., Gao, Z., & Xia, X. (2026). S1PR-Targeted PET Imaging: Advancing Insights into Neuroinflammatory and Immune-Related Pathologies. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01259

Vancouver

Wu R, Rong J, Hou Y, Yin C, Zhou Y, Gai Y, et al. S1PR-Targeted PET Imaging: Advancing Insights into Neuroinflammatory and Immune-Related Pathologies. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01259

BibTeX
@article{Wu2026,
  author = {Wu, Ruolin and Rong, Jian and Hou, Yuyue and Yin, Chenru and Zhou, Yan and Gai, Yongkang and Haider, Achi and Lan, Xiaoli and Liang, Steven H and Gao, Zairong and Xia, Xiaotian},
  title = {S1PR-Targeted PET Imaging: Advancing Insights into Neuroinflammatory and Immune-Related Pathologies},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01259}
}
Kostenlos starten →